Peer Network

Welcome to the Peer Network

 

PEER Network Web Site Privacy Statement

PLEASE READ THIS PRIVACY STATEMENT CAREFULLY. Privacy is very important to us. We also understand that privacy is very important to you. This Privacy Statement tells you how we protect and use information that we gather through this United Therapeutics Corporation Web site. United Therapeutics Corporation and its affiliates also operate other Web sites. This Privacy Statement does not apply to the other United Therapeutics Corporation Web sites. You should review the privacy statement posted on other United Therapeutics Corporation Web sites when you visit them. This Web site and this Privacy Statement are intended only for audiences in the U.S.

This Privacy Statement was last revised on April 15, 2010. We may change this Privacy Statement at any time and for any reason. Significant changes to the Privacy Statement are discussed below in the Section called "Changes to the Privacy Statement." We encourage you to review this Privacy Statement each time you visit the Web site.

By using this Web site, you agree to the terms of the most recent version of this Privacy Statement. Please read our Terms of Use to understand the general rules about your use of this Web site. Except as written in any other disclaimers, policies, Terms of Use, or other notices on this Web site, this Privacy Statement and the Terms of Use are the complete agreement between you and United Therapeutics Corporation with respect to your use of this Web site.

INTRODUCTION

We are pleased to post this policy so that users understand how we utilize the information they provide us. For other important information concerning your use of our site, please refer to our Terms of Use. United Therapeutics Corporation respects the privacy of those who use its site. Users should understand, however, that by the very nature of the medium, their communications with us, such as postings to the site or e-mail, reveal their e-mail addresses and other potentially identifying information. The information we receive, and how we use it, depends on what you do when visiting our Web site. We collect and use your non-personal information (information that is not identifiable to you personally) differently than your personal information.

WHAT IS NON-PERSONAL INFORMATION?

Non-personal information is information we collect through this Web site that does not identify you as an individual person. It includes any of the following items:

  • The type of Web browser software you use (for example, Netscape Navigator or Internet Explorer)
  • The name of the domain from which you access the Internet (including client and server IP addresses, usernames, ports, queries, or other status-related information)
  • The Internet address of the Web site from which you linked directly to our Web site
  • The date and time you access our Web site
  • Which pages you have visited on our Web site

WHAT DOES UNITED THERAPEUTICS CORPORATION DO WITH NON-PERSONAL INFORMATION?

Because non-personal information cannot identify you or be tied to you in any way, there are few restrictions on the ways that we can use or share non-personal information. Primarily, we will use this data to make enhancements to the Web site that are specifically tailored to improve the experience of the user community. One way that we use non-personal information is to demonstrate user trends on the Web site. Often, this is done by aggregating the data gleaned from non-personal information. This aggregated, de-identified data might be shared with outside parties who are employed to implement improvements to the site.

WHAT IS PERSONAL INFORMATION?

Personal information is information we collect through this Web site that we can use to specifically identify you, such as your:

  • Name
  • Telephone number
  • E-mail address
  • State of residence
  • Age range
  • Gender
  • Name of your physician
  • Whether you are a patient or a caregiver
  • Why you are participating in the program

In some places on this Web site you have the opportunity to send us personal information about yourself. For example, you may fill out a registration form, a survey, or an e-mail form. Any personal information that you enter on this Web site will not be revealed to third parties or used for any purpose outside of United Therapeutics Corporation.

HOW DOES UNITED THERAPEUTICS CORPORATION KEEP AND USE PERSONAL INFORMATION?

Please note, United Therapeutics Corporation and its agents comply with HIPAA (Health Information Portability and Accountability Act) in the collection and use of your personally identifiable health information. When you register for the PEER Network and sign the HIPAA waiver, you are giving United Therapeutics Corporation and Health Advocacy Strategies™ permission to use your personal information to communicate with you. Your information will never be shared with a third party, except as outlined below.

We may keep and use personal information we collect from you through this Web site to provide you with access to this Web site. In addition, we may keep and use your personal information:

  • To administer this program
  • To respond to your requests
  • To develop records, including records of your personal information
  • For internal program monitoring. Never for personal purposes.
  • To remove your personal identifiers (your name, e-mail address, etc.) In this case, you would no longer be identified as a single unique individual. Once we have de-identified information, it is non-personal information and we may treat it like other non-personal information.
  • To enforce this Privacy Statement and other rules about your use of this Web site
  • To protect our rights or property
  • To protect someone's health, safety or welfare
  • To comply with a law or regulation, court order or other legal process
Information Collection Specific to PEER Network Patient-to-Patient Program

In order to participate in the PEER Network patient-to-patient program, you will be required to provide personal and contact information. Information is collected in order to provide you with the most personalized experience possible and for internal program monitoring. It is not used for any other purposes or programs. Information provided will remain confidential in accordance with United Therapeutics Corporation’s Privacy Statement.

What Information is Collected?

We collect contact information, including your name, e-mail, phone number(s), and state of residence. We also collect your age range, gender, and the name of the physician who treats you for pulmonary arterial hypertension (PAH). We ask you to indicate if you are a parent or caregiver and why you are participating in the program. We also ask you the purpose for choosing a PEER Mentor. Finally, we ask you to choose a User Name and password. From time to time, we also ask that you respond to surveys, which help to evaluate your satisfaction with the program.

How the Information is Used

We respect the information you submit. Your information will be used only for internal program monitoring. This may include looking at trends regarding current or planned United Therapeutics Corporation product use, discontinuation, and concomitant use of other medications to treat PAH; the names of doctors from program users; and the states in which users live. Program staff will also use survey data to monitor trends in Web site user attitudes toward and satisfaction with the program. This includes average response time of Mentors, whether you might recommend this program to others, your suggestions as to how we might improve the program, if you are currently receiving a United Therapeutics Corporation product and/or other medications to treat your PAH. It will not be used for personal reporting purposes. This means we will never tie your name with your other personal information in our reporting and evaluation of the program.

We will not use, sell, or assign your e-mail address for any purpose other than to communicate with you about the PEER Network.

Your password will be used to keep your information secure and help us build your personalized Web page when you login.

Your age range, gender, User Name, and why you are seeking a Mentor will be shared with your Mentor. This information will help your Mentor better understand your circumstances and provide you with a meaningful experience.

DOES UNITED THERAPEUTICS CORPORATION EVER SHARE PERSONAL INFORMATION WITH THIRD PARTIES?

United Therapeutics Corporation will not share your personal information collected from this Web site with an unrelated third party without your permission.

In the ordinary course of business, we will share some personal information with companies that we hire to perform services or functions on our behalf. For example, we employ a company to develop and maintain this Web site. In this case, the company will have access to your personal information in the ordinary course of business. However, in this instance, and all instances in which your personal information is shared with a third party, we will not authorize them to keep, disclose or use your information with others except for the purpose of providing the services we asked them to provide.

We will not sell, exchange or publish your personal information, except in conjunction with a corporate sale, merger, dissolution, or acquisition.

We may be legally compelled to release your personal information in response to a court order, subpoena, search warrant, law or regulation. We may cooperate with law enforcement authorities in investigating and prosecuting Web site visitors who violate our rules or engage in behavior which is harmful to other visitors (or illegal).

We may disclose your personal information to third parties if we feel that the disclosure is necessary to:

  • To administer this program
  • Enforce the Privacy Statement and other rules about your use of this web site
  • Protect our rights or property
  • Protect someone's health, safety, or welfare
  • Comply with a law or regulation, court order or other legal process

Please note: In addition to the ways that we may keep, disclose, and use information described in this Privacy Statement, we also may keep, disclose, and use personally identifiable information that you give us through this Web site in ways that we believe are consistent with FDA and other governmental guidance, directions, regulations, and laws.

WHAT HAPPENS IF THE PRIVACY STATEMENT CHANGES?

If we decide to make a significant change to our Privacy Statement, we will post a notice on the homepage of our Web site for thirty (30) days after the change is made. United Therapeutics Corporation reserves the right to change the terms of our Privacy Statement at any time in its sole discretion. Please periodically revisit this page to stay current on any changes and to update your preferences accordingly.

WHAT ABOUT PRIVACY ON OTHER WEB SITES?

This Web site may contain links to other Web sites. Some of those Web sites may be operated by United Therapeutics Corporation, and some may be operated by third parties. We provide the links for your convenience, but we do not review, control, or monitor the activities or privacy practices of Web sites operated by others, and we do not endorse, condone, adopt, or accept liability for any statements made on Web sites to which we provide links. This Privacy Statement does not apply to any other Web site, even those owned by United Therapeutics Corporation. We are not responsible for the performance of Web sites operated by third parties or for your business dealings with them. Therefore, whenever you leave this Web site, we recommend that you review each Web site's privacy practices and make your own conclusions regarding the adequacy of these practices.

DOES UNITED THERAPEUTICS CORPORATION EVER COMMUNICATE DIRECTLY WITH VISITORS TO THIS WEB SITE?

With your express permission, we may contact you periodically by e-mail, mail or telephone to provide information regarding programs, services and content that may be of interest to you. In addition, some of the features on this Web site allow you to communicate with us using an online form. If your communication requests a response from us, we will send you a response via e-mail. The e-mail response or confirmation may include your personal information, including personal information about your health, your name, address, etc. We cannot guarantee that our e-mails to you will be secure from unauthorized interception.

ARE THERE SPECIAL RULES ABOUT CHILDREN'S PRIVACY?

We care about protecting the online privacy of children. This Web site is not intended for use by children under the age of 18. We will not intentionally collect any personal information (such as a child's name or e-mail address) from children under the age of 18. If you are a child under age 18, please do not send us any information about yourself. If you think that we have collected personal information from a child under the age of 18, please contact us. We encourage all parents and guardians to monitor their children’s use of the Internet.

WHAT ABOUT WEB SITE SECURITY?

We take reasonable steps to protect your personal information from loss, misuse, and unauthorized access, disclosure, alteration, or destruction. You should keep in mind that no Internet transmission is ever 100% secure or error-free. In particular, e-mail sent to or from this site may not be secure, and you should therefore take special care in deciding what information you send to us via e-mail.

HOW TO CONTACT UNITED THERAPEUTICS CORPORATION

If you have questions or comments about this Privacy Statement, please contact:

Alyssa Friedrich
Senior Vice President, Human Resources & Corporate Development
United Therapeutics Corporation
afriedrich@unither.com

THE PEER NETWORK IS INTENDED FOR U.S. AUDIENCES ONLY. This PEER Network program and Web site are sponsored by United Therapeutics Corporation. Program participation, product copy and claims are intended only for residents of the United States. Products sold under the same brand names outside of the United States may be subject to different regulatory approvals and standards. If you are located outside of the United States, please consult with your local physician or pharmacy for information about Tyvaso® (treprostinil) Inhalation Solution or Remodulin® (treprostinil) Injection.

Reporting Adverse Events
Please note that this Web site does not collect or report adverse events. If you are taking Tyvaso or Remodulin and have experienced or are experiencing a potential adverse event, please inform your healthcare provider.

Tyvaso® (treprostinil) Inhalation Solution

INDICATION
Tyvaso is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH) (WHO Group 1), which is high blood pressure in the arteries of your lungs. Tyvaso can improve exercise ability in people who also take bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase-5 inhibitor). The effects decrease over 4 hours; treatment timing can be adjusted for planned activities.

Studies establishing effectiveness included predominately patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).

IMPORTANT SAFETY INFORMATION for Tyvaso

  • Tyvaso is breathed in (inhaled) through your mouth into your lungs. Tyvaso should only be used with the Tyvaso Inhalation System.
  • The effects of Tyvaso are unknown in patients with lung disease (such as asthma or chronic obstructive pulmonary disease) and in patients under 18 years of age.
  • If you have low blood pressure, Tyvaso may cause symptomatic hypotension (low blood pressure).
  • Because Tyvaso reduces the ability of your blood to clot (coagulate), it may increase your risk for bleeding if you are taking blood thinners (anticoagulants), such as warfarin or heparin.
  • The use of Tyvaso with diuretics (water pills), antihypertensives (medications used to treat high blood pressure or heart disease), or other vasodilators (medications that lower blood pressure) may increase your risk for hypotension (low blood pressure).

Other medical conditions and medicines may affect your use of Tyvaso by increasing the risk of side effects or decreasing effectiveness. It is important to tell your doctor about your medical conditions and any medicines you may be taking, including:

  • If you are taking gemfibrozil (for high cholesterol) or rifampin (for infection), your Tyvaso dosage may need adjustment.
  • If you have liver or kidney problems, your ability to tolerate Tyvaso may be affected.
  • If you are pregnant, breast-feeding, or planning to become pregnant, talk with your healthcare provider about whether you should take Tyvaso.

The most common side effects of Tyvaso are coughing, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), and fainting or loss of consciousness. These are not all the possible side effects of Tyvaso. Tell your doctor about any side effects that bother you or do not go away. Your doctor may be able to help you manage the side effects.

For additional information about Tyvaso, please see accompanying Full Prescribing Information, Patient Package Insert and the Tyvaso Inhalation System Instructions for Use manual, visit www.tyvaso.com, or call 1-877-864-8437.

Remodulin® (treprostinil) Injection

INDICATION
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion; however, because of the risks associated with chronic indwelling central venous catheters, including serious blood stream infections, continuous intravenous infusion should be reserved for patients who are intolerant of the subcutaneous route, or in whom these risks are considered warranted.

In patients with PAH requiring transition from Flolan® (epoprostenol sodium), Remodulin is indicated to diminish the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.

IMPORTANT SAFETY INFORMATION for Remodulin

  • Chronic intravenous infusions of Remodulin are delivered using an indwelling central venous catheter. This route is associated with the risk of blood stream infections (BSI) and sepsis, which may be fatal. Therefore, continuous subcutaneous infusion is the preferred mode of administration.
  • Remodulin should be used only by clinicians experienced in the diagnosis and treatment of PAH.
  • Remodulin is a potent pulmonary and systemic vasodilator. It lowers blood pressure, which may be further lowered by other drugs that also reduce blood pressure.
  • Remodulin inhibits platelet aggregation and therefore, may increase the risk of bleeding, particularly in patients on anticoagulants.
  • Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
  • Initiation of Remodulin must be performed in a setting with adequate personnel and equipment for physiological monitoring and emergency care.
  • Therapy with Remodulin may be used for prolonged periods, and the patient’s ability to administer Remodulin and care for an infusion system should be carefully considered.
  • Remodulin dosage should be increased for lack of improvement in, or worsening of, symptoms and it should be decreased for excessive pharmacologic effects or for unacceptable infusion site symptoms.
  • Abrupt withdrawal or sudden large reductions in dosage of Remodulin may result in worsening of PAH symptoms and should be avoided.
  • Caution should be used in patients with hepatic or renal insufficiency.
  • The most common side effects of Remodulin included those related to the method of infusion. For subcutaneous infusion, infusion site pain and infusion site reaction (redness and swelling) occurred in the majority of patients. These symptoms were often severe and could lead to treatment with narcotics or discontinuation of Remodulin. For intravenous infusion, line infections, sepsis, arm swelling, tingling sensations, bruising, and pain were most common. General side effects (>5% more than placebo) were diarrhea, jaw pain, vasodilatation and edema.

For additional information about Remodulin, please see the Full Prescribing information, visit http://www.remodulin.com, or call 1-877-864-8437.